LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
-0.29 (-0.25%)
At close: 4:03PM EST

118.15 +1.35 (1.16%)
Pre-Market: 8:15AM EST

Stock chart is not supported by your current browser
Previous Close117.09
Bid115.00 x 900
Ask118.11 x 1000
Day's Range116.48 - 118.07
52 Week Range73.69 - 119.84
Avg. Volume4,712,374
Market Cap114.795B
Beta (3Y Monthly)0.59
PE Ratio (TTM)268.51
EPS (TTM)0.44
Earnings DateFeb 13, 2019
Forward Dividend & Yield2.25 (1.94%)
Ex-Dividend Date2018-11-14
1y Target Est117.47
Trade prices are not sourced from all markets
  • Dealmaking surge confirms the stock market got far too ch...
    CNBC Videos14 hours ago

    Dealmaking surge confirms the stock market got far too ch...

    Jim Cramer explains why there's been more merger and acquisition activity in recent months and says it's "just getting started."

  • Citron Says Ligand Has 80% Downside in Explosive Note
    Investopedia2 hours ago

    Citron Says Ligand Has 80% Downside in Explosive Note

    Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.

  • TheStreet.com14 hours ago

    Jim Cramer: There's a Ton More Deals in the Pipe

    The acquirers are snapping up targets like mad because the targets have seen their stocks collapse from the Great Bear Market of 2018, also known as the Powell-Pow Bear market, because Jay Powell hit stocks Pow! right in the kisser when he set out his automaton rate increase plan at the beginning of October. The creation of this new financial technology payments company is a huge win for First Data shareholders who owned a $17 stock just yesterday. David Faber on CNBC reported that these two companies had been talking for months.

  • GuruFocus.com16 hours ago

    5 Health Care Stocks in Gurus' Portfolios

    Eli Lilly tops the list

  • Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
    Zacks17 hours ago

    Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings

    Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.

  • Intrexon Signs Licensing Agreement with Next Green Wave
    Zacks17 hours ago

    Intrexon Signs Licensing Agreement with Next Green Wave

    Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.

  • Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It
    Investor's Business Daily17 hours ago

    Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It

    Ligand Pharmaceuticals stock crashed to nearly a two-year low Wednesday after short-seller Citron Research slammed the biotech stock for having "80% downside from its current levels."

  • TheStreet.com20 hours ago

    Goldman's Gold Standard in M&A Bolsters Outlook for 2019

    Goldman Sach's presents a golden opportunity for those bullish on M&A activity in 2019. Shares of the big bank have soared in mid-day trading, bolstered by a big earnings beat that was helped in no small part by huge profits in M&A advisory.

  • Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming
    Investor's Business Daily20 hours ago

    Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming

    Takeda Pharmaceutical wrapped its $62 billion acquisition of Shire last week. CEO Christophe Weber predicts it won't be the last merger in the hot biopharma sector.

  • 6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019

    6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019

    Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.

  • Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
    Investor's Business Daily2 days ago

    Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter

    Incyte stock launched Tuesday after an analyst suggested its portfolio of cancer treatments could net the biotech stock an acquisition offer. Biotech deals have been rampant this month.

  • GlobeNewswire2 days ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders

    NEW YORK, Jan. 15, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Loxo Oncology, Inc. (“Loxo.

  • Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
    Zacks2 days ago

    Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer

    Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Eli Lilly and Co.

    # Eli Lilly and Co ### NYSE:LLY View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for LLY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $14.44 billion over the last one-month into ETFs that hold LLY are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. LLY credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Eli Lilly CEO Predicts 2019 Will Be Big Year for Biotech Acquisitions
    GuruFocus.com3 days ago

    Eli Lilly CEO Predicts 2019 Will Be Big Year for Biotech Acquisitions

    Eli Lilly and Co. (LLY) CEO David Ricks thinks two recent biotechnology acquisitions by big pharma could open the floodgates for more deals in 2019. Speaking at the recent J.P. Morgan Healthcare Conference in San Francisco, Ricks said the stars are aligned for heightened merger and acquisition activity in the field. Lilly welcomed the new year by announcing it was buying Stamford, Connecticut-based Loxo Oncology (LOXO) in an $8 billion deal.

  • Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
    Zacks3 days ago

    Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

    Eli Lilly (LLY) closed at $114.68 in the latest trading session, marking a -1.29% move from the prior day.

  • Will Biogen Jump On This Biotech Stock Amid Buying Spree?
    Investor's Business Daily3 days ago

    Will Biogen Jump On This Biotech Stock Amid Buying Spree?

    Alder Biopharmaceuticals could eventually capture 15%-20% of the market for migraine prevention, an analyst said Monday, suggesting the biotech stock might be a good fit for giant Biogen.

  • CNBC3 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • Here's Why Eli Lilly Stock Surged 37% in 2018
    Motley Fool4 days ago

    Here's Why Eli Lilly Stock Surged 37% in 2018

    The big pharma company made all the right moves in 2018.

  • Benzinga4 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    M&A momentum is building in the pharma space, with more deals announced last week, including Eli Lilly And Co (NYSE: LLY )'s $8-billion move to acquire Loxo Oncology Inc (NASDAQ: LOXO ). The following ...

  • Here's Why Loxo Oncology Soared 66.4% in 2018, and Another 66% Since
    Motley Fool4 days ago

    Here's Why Loxo Oncology Soared 66.4% in 2018, and Another 66% Since

    The biopharma delivered the goods with its drug pipeline, scored marketing approval for its lead drug candidate, and agreed to be acquired for $8 billion.

  • 5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019
    Zacks6 days ago

    5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019

    Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.

  • Stock Market Rally Runs Into Resistance; Boeing, GM, Macy's, American Airlines: Weekly Review
    Investor's Business Daily6 days ago

    Stock Market Rally Runs Into Resistance; Boeing, GM, Macy's, American Airlines: Weekly Review

    The stock market continued to run higher in the latest week, despite warnings from Macy's, American Airlines and Constellation Brands. GM and Boeing rallied on good news.

  • Reuters6 days ago

    Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

    Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two of the hottest areas of drug development. Lilly Chief Executive Dave Ricks told Reuters that as the company looks for deals to enhance its pipeline of future treatments it will leave CAR-T therapies for cancer and gene therapy for rare diseases to others, for now. "The data is amazing, but practically, it's not reaching many people," Ricks said of CAR-T therapy, which involves extracting disease-fighting T-cells from a patient, re-engineering them to better recognize and attack cancer, and reinfusing them into the body.

  • 7 Pharmaceutical Stocks That Just Raised Prices This Year
    InvestorPlace6 days ago

    7 Pharmaceutical Stocks That Just Raised Prices This Year

    Given the meltdown we've seen across the entire market over the past 16 weeks, many investors may be overlooking company-specific and industry-specific news. One of those pieces of news? That a swath of pharmaceutical stocks are raising their prices in the new year. Pharmaceutical stocks and biotech companies are interesting plays in any market, partly due to their secular business nature. Meaning that, recession or boom, consumers need treatment. Whether it's as large as open heart surgery or small as a Tylenol, we pay for healthcare when we need it. For as secular as the group can be though, it has been under tremendous volatility lately. With that in mind, almost 40 companies started of 2019 with a series of prices hikes. The average raise was roughly 6.3%. So who were these companies and how do we trade their stocks? InvestorPlace - Stock Market News, Stock Advice & Trading Tips * InvestorPlace Roundup: The Hottest Stocks in the Market Today Let's look at a few of those pharmaceutical stocks. ### Allergan (AGN) Allergan (NYSE:AGN) is known for its vast drug and treatment portfolio. However, at the turn of the year, Allergan raised prices on 51 of its products. That's just over half of its portfolio. Of those 51 products, 27 of them saw an increase of 9.5%. The rest were bumped by 4.9%. All that said, Allergan makes the case that it's not a money-hungry cash grab. Rather, the company says it should not see any net gains as a result of the price hikes because it's providing higher rebates and discounts to its distributors. Allergan may say that, but investors sure wish it would help. Analysts expect sales to fall 1.7% this year and another 1.6% next year. On the earnings front, expectations call for a 90-basis-point gain this fiscal year before a 0.7% decline in 2019. Essentially, estimates call for flat earnings growth overall from fiscal 2017 through 2019. That's likely one factor for why the stock has gone from $195 in October to roughly $125 at its December lows. As AGN approaches the $145 to $150 level now, look to see if and where resistance comes into play. There's downtrend resistance at play, as well as the gap-fill up near $145. It would be encouraging to see the $140-ish level hold as support, but that doesn't leave much wiggle room for Allergan. ### Bristol-Myers (BMY) No one is talking about recent dividend payout from Bristol-Myers Squibb (NYSE:BMY), nor are they talking about its recent price increases. The company raised prices on its cancer drugs Opdivo and Yervoy by 1.5%, while lifting prices by 6% on its chemotherapy treatment Sprycel and its autoimmune disease drug Orencia. However, most investors are talking about the company's $74 billion cash and stock acquisition of Celgene (NASDAQ:CELG). BMY was hammered on the news at first, but rebounded by about 4% on Friday once investors were able to digest the news. Management expects the deal to close in the third quarter of 2019. Creating over $2 billion in synergies and boosting growth, BMY management is hoping the acquisition makes its stock more attractive to investors. At just 12 times forward earnings with 8.5% sales growth and 28% earnings growth this year, BMY already looks reasonable. Throw in its 3.5% dividend yield and its even more attractive. * Morgan Stanley: 7 Risky Stocks to Sell Now On the charts, it's clear that dips down to the upper $40s have been viewed as buying opportunities by investors over the last four years. ### Eli Lilly (LLY) Eli Lilly (NYSE:LLY) isn't exempt when it comes to drug price increases, as it raises prices for Jardiance, a treatment for type 2 diabetes, by 6%. Unlike some of its peers, Eli Lilly has been on absolute fire. Shares are up 35% year-over-year and about 60% from its February lows. Despite the rally, LLY still pays out a 2.2% dividend yield and trades at a somewhat reasonable 20.6 times this year's earnings. Despite the big breakout rally in July, LLY has modest growth expectations. Analysts expect 6.8% and 4% sales growth this year and next year, respectively. Further, estimates call for 30.4% earnings growth this year and 6.5% growth in 2019. Fueling the breakout during the summer? A strong second-quarter result and potential IPO for one of its businesses. However, some may feel that LLY stock has rallied too far, too fast and that it's no longer a worthy buy. According to the charts, that may be the case if LLY is unable to push higher and take out its recent highs near $120. If it can break that level, the rally can continue. If not, look to see if uptrend support holds (blue line). Should it fail, LLY could be heading for a retest of its 200-day moving average. ### Pfizer (PFE) Pfizer (NYSE:PFE) delayed various price hikes in 2018, but pushed through its increases at the start of the year. Not many companies have been as open as Allergan about confirming its specific price hikes, but Pfizer may need them to keep pace in 2019. That is to say, PFE was one of the best-performing stocks in the Dow Jones last year. After consolidating between $30 and $36 for most of the last five years, shares finally broke out around the same time Eli Lilly did. In fact, their charts look quite similar too. After a big breakout six months ago, PFE is having trouble pushing higher. Should it fail to get through the 50-day and short-term uptrend support (blue line) gives way, a test of the 200-day moving average could be in the cards. Should it fail as support, a test of $38 is likely in store. Above the 50-day and a rally to $46 is possible. * 10 Stocks You Can Set and Forget (Even In This Market) Investors not worried about the charts will key in on Pfizer's 3.4% dividend yield and its valuation of 14 times this year's earnings. Although remember that 2018's 13.2% earnings growth is expected to slow to just 2.7% in 2019. ### Biogen (BIIB) Biogen (NASDAQ:BIIB) was also on the list of price increases for 2019. The company increased prices on its multiple sclerosis medications Tecfidera by 6%, Plegridy by 2% and Tysabri by 3.5%. Like other biotech stocks, Biogen has been volatile and struggling. Nowhere is this more evident than on the charts. Shares went from $370 in February to $250 in a matter of months, then hit nearly $400 per share in late July. Now near $330, BIIB bulls are near a make-or-break point. The stock has put in a series of lower highs (blue circles) since that big rally in July. Currently, both the 50-day and the 200-day moving averages rest at about $313. Investors who believe BIIB is attractive -- trading at about 12 times forward earnings with expectations to grow sales and earnings 2.5% and 8.5% in 2019, respectively -- will want to see it hold above these two marks. Should it fail, Biogen could quickly head to the bottom of its recent channel, somewhere in the $270 range. On the plus side though, if shares push higher and can close above $340, BIIB may be starting a new uptrend. ### Teva (TEVA) While Warren Buffett's Berkshire Hathaway (NYSE:BRK.B, NYSE:BRK.A) holds a $750 million stake in Teva Pharmaceuticals (NYSE:TEVA), it's far from his largest holding. Big or small, the Oracle has to be disappointed with the stock's recent action, falling from $24 in November to less than $15 at its lows last month. Now up over $17, bulls are hoping Teva stock can continue higher. Will it? Like the others on this list, Teva also raised prices on some of its drugs this year, although the specifics are not well known. So far the name has done well this year, though granted, were just a few sessions into 2019. In any regard, Teva is bumping into the backside of prior downtrend support (blue line). Should this level act as resistance, bulls will want $16.75 to act as support. If not, the recent lows are in play. Over resistance and the $19 to $20 level is on the table. * The 7 Best Stocks in the Entrepreneur Index While the stock trades at less than 7 times this year's earnings, keep in mind that growth has been tough. Sales are forecast to fall 15.8% this year, while analysts expect earnings to contract by 27%. In 2019, the slowdown decelerates, but analysts are still calling for a 4.8% reduction in revenue and a 3% fall in earnings. ### Insys Therapeutics (INSY) Though it is much smaller than most of the names on this list, Insys Therapeutics (NASDAQ:INSY) is joining them in raising prices -- in this case, on its pain-relief medication Subsys. INSY has a market cap of just $350 million. The move is probably necessary, given that sales are forecast to fall about 40.5% this year and another 5% in 2019. It doesn't help that INSY doesn't turn a profit, although its lack of debt is encouraging. Given the selloff we've seen in the stock market since the start of Q4 2018, it's no surprise that investors have cut INSY very little slack. Shares came into Q4 near $10, but are now clinging to the $4.25 level. To say it's been a rough ride would be an understatement. However, INSY is holding up over the $4 level and is right at downtrend resistance. A push higher to $5 would be encouraging, even if this level acts as resistance on its first attempt. But a break below $4 -- especially in the near-term -- would be worrisome and puts the lows back on the table. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 7 Pharmaceutical Stocks That Just Raised Prices This Year appeared first on InvestorPlace.